Thorvardur Halfdanarson: Cabozantinib in previously treated advanced NETs
Thorvardur Halfdanarson, Professor of Oncology at Mayo Clinic School of Medicine, shared a post on X:
“Hot off the press, Alliance CABINET!
Cabozantinib in previously treated (93% had SSA, 60% had PRRT, 72% had everolimus) advanced NETs.
The primary endpoint, PFS, was significantly better in the cabo arm than placebo.”
Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors
Authors: Jennifer A. Chan, Susan Geyer, Tyler Zemla, Michael V. Knopp, Spencer Behr, Sydney Pulsipher,Fang-Shu Ou, Ph.D., Amylou C. Dueck, Jared Acoba, Ardaman Shergill, Edward M. Wolin, Thorvardur R. Halfdanarson, Bhavana Konda, Nikolaos A. Trikalinos, Bernard Tawfik, Nitya Raj, Shagufta Shaheen, Namrata Vijayvergia, Arvind Dasari, Jonathan R. Strosberg, Elise C. Kohn, Matthew H. Kulke, Eileen M. O’Reilly and Jeffrey A. Meyerhardt.
Source: Thor Halfdanarson/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023